Close Menu

NEW YORK – Oncocyte said on Thursday that it has entered a distribution agreement with ProGenetics, expanding the commercial availability of its DetermaRx test to Israel. Financial and other terms were not disclosed.

DetermaRx is a treatment stratification test that identifies patients at high risk for lung cancer recurrence who may benefit from adjuvant chemotherapy after tumor removal surgery. Oncocyte launched the test in the United States through an early-access program in late January, which it said has now expanded to over 40 sites.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.